UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 319

Sortiert nach

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

The New England journal of medicine, 2014-05, Vol.370 (19), p.1809-1819

2014

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.341-350

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509

2015

Link zum Volltext

Verfügbarkeit prüfen

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

The New England journal of medicine, 2019-08, Vol.381 (6), p.531-542

2019

Link zum Volltext

Verfügbarkeit prüfen

A report card for healthy aging in South Africa

Cardiovascular Journal of Africa, 2022-07, Vol.33 (4), p.5-6

Blom, Dirk J

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Circulation (New York, N.Y.), 2017-07, Vol.136 (3), p.332-335

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Journal of the American College of Cardiology, 2020-02, Vol.75 (6), p.565-574

2020

Link zum Volltext

Verfügbarkeit prüfen

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2010-03, Vol.375 (9719), p.998-1006

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial

Journal of the American College of Cardiology, 2020-07, Vol.76 (2), p.131

2020

Link zum Volltext

Verfügbarkeit prüfen

Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies

Atherosclerosis, 2018-10, Vol.277, p.502-507

2018

Link zum Volltext

Verfügbarkeit prüfen

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

European heart journal, 2018-04, Vol.39 (14), p.1162-1168

2018

Link zum Volltext

Verfügbarkeit prüfen

Volatile-Mediated Killing of Arabidopsis thaliana by Bacteria Is Mainly Due to Hydrogen Cyanide

Applied and Environmental Microbiology, 2011-02, Vol.77 (3), p.1000-1008

2011

Link zum Volltext

Verfügbarkeit prüfen

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

Orphanet journal of rare diseases, 2018-06, Vol.13 (1), p.96-96, Article 96

2018

Link zum Volltext

Verfügbarkeit prüfen

Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms

Current atherosclerosis reports, 2022-06, Vol.24 (6), p.399-405

2022

Link zum Volltext

Verfügbarkeit prüfen

Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis

Current atherosclerosis reports, 2019-11, Vol.21 (12), p.48-48, Article 48

2019

Link zum Volltext

Verfügbarkeit prüfen

Lipoprotein metabolism in familial hypercholesterolemia

Journal of lipid research, 2021-01, Vol.62, p.100062-100062, Article 100062

2021

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

Circulation (New York, N.Y.), 2011-11, Vol.124 (20), p.2202-2207

2011

Link zum Volltext

Verfügbarkeit prüfen

Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study

Circulation research, 2015-09, Vol.117 (8), p.731-741

2015

Link zum Volltext

Verfügbarkeit prüfen

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab

Arteriosclerosis, thrombosis, and vascular biology, 2018-03, Vol.38 (3), p.592

2018

Link zum Volltext

Verfügbarkeit prüfen

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096

2016

Link zum Volltext

Verfügbarkeit prüfen

Carl Jung: a life on the edge of reality with hypnagogia, hyperphantasia, and hallucinations

Frontiers in psychology, 2024, Vol.15, p.1358329-1358329

2024

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288

2014

Link zum Volltext

Verfügbarkeit prüfen

The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study

European journal of preventive cardiology, 2020-09, Vol.27 (13), p.1403-1411

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 319

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(241)
Mit Volltextzugriff
(291)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

A report card for healthy aging in South Africa

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

Volatile-Mediated Killing of Arabidopsis thaliana by Bacteria Is Mainly Due to Hydrogen Cyanide

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms

Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis

Lipoprotein metabolism in familial hypercholesterolemia

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Carl Jung: a life on the edge of reality with hypnagogia, hyperphantasia, and hallucinations

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study

Suchergebnisse filtern